Term ends no later than Feb 10, 2029 · Medium confidence
20-year base term ended Feb 3, 2026
In force on USPTO's status record and by its fee record. A terminal disclaimer on file may shorten this term, possibly to a date already past; its reference document is unresolved, so the date above is an upper bound and no earlier date is guessed.
Feb 3, 2006
Feb 10, 2029
Nov 8, 2011
This patent's term runs 1103 days past its 20-year base term on prosecution delay. A terminal disclaimer is on file with no resolved reference, so no cap is applied and none is guessed. All three maintenance fees are recorded paid; no more fees are due. Confidence: Medium. from the record
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Feb 3, 2006, when application 11/347,562, the earliest non-provisional in its chain, was filed (this one was filed May 30, 2007) | Feb 3, 2026 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +1103 days, USPTO patent term adjustment record | Feb 10, 2029 | High confidence |
| Terminal disclaimer cap | Disclaimer on file (approved), reference document not resolved | no cap applied, and none guessed | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | no later than Feb 10, 2029 | Medium confidence |
This family
| US 8,114,437 | In force Aug 2027 | Aug 2027 |
| US 8,052,996 | this patent no later than Feb 2029 | no later than Feb 2029 |
| US 8,299,025 | Term ended Feb 2026 | Feb 2026 |
| US 8,211,467 | Term ended Feb 2026 | Feb 2026 |
| US 8,940,316 | In force no later than Jan 2029 | no later than Jan 2029 |
| US 8,206,745 | Term ended Feb 2026 | Feb 2026 |
| US 8,158,150 | Term ended Feb 2026 | Feb 2026 |
| US 8,273,365 | Term ended Feb 2026 | Feb 2026 |
Assignments
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Oct 26, 2007 Reel 20035, frame 441 | Alza Corporation | Intarcia Therapeutics, Inc. | Assignment of Assignor's Interest |
| Nov 19, 2007 Reel 20141, frame 531 | Lautenbach, Scott D.; De La Serna, Pedro E.; Zamora, Pauline C.; Desjardin, Michael A. | Intarcia Therapeutics, Inc. | Assignment of Assignor's Interest |
| Oct 8, 2008 Reel 21660, frame 757 | Lautenbach, Scott D.; De La Sema, Pedro E.; Zamora. Pauline C; Desjardin, Michael A. | Alza Corporation | Assignment of Assignor's Interest |
| Sep 8, 2010 Reel 24953, frame 525 | Intarcia Therapeutics, Inc. | Oxford Finance Corporation; Silicon Valley Bank | Security Agreement |
| Sep 8, 2010 reel/frame not recorded | Intarcia Therapeutics, Inc. | Oxford Finance Corporation | Security Agreement |
| Sep 8, 2010 reel/frame not recorded | Intarcia Therapeutics, Inc. | Silicon Valley Bank | Security Agreement |
| Aug 9, 2011 Reel 26722, frame 45 | Lautenbach, Scott D.; De La Serna, Pedro E.; Zamora, Pauline C.; Desjardin, Michael A. | Intarcia Therapeutics, Inc. | Assignment of Assignor's Interest |
| Sep 23, 2011 Reel 26962, frame 62 | Oxford Finance Corporation; Silicon Valley Bank | Intarcia Therapeutics, Inc. | Release of Security Interest |
| Nov 14, 2012 Reel 29299, frame 678 | Intarcia Therapeutics, Inc. | U.S. Bank National Association, as Collateral Agent | Security Agreement |
| Oct 23, 2015 Reel 36942, frame 544 | U.S. Bank National Association, as Collateral Agent | Intarcia Therapeutics, Inc. | Release of Security Interest |
| Oct 9, 2019 Reel 50673, frame 20 | Intarcia Therapeutics, Inc.; Intarcia Ireland Limited | Midcap Financial Trust, As Agent | Security Interest |
| Oct 23, 2019 Reel 50801, frame 267 | Intarcia Therapeutics, Inc. | Baupost Private Investments Bviv-3, L.L.C., as Collateral Agent | Security Interest |
| Jan 29, 2020 Reel 51739, frame 453 | Baupost Private Investments Bviv-3, L.L.C. as Collateral Agent | Intarcia Therapeutics, Inc. | Release of Security Interest |
| Apr 17, 2020 Reel 52433, frame 1 | Midcap Financial Trust, As Agent | Intarcia Therapeutics, Inc.; Intarcia Ireland Limited | Release of Security Interest |
| Apr 17, 2020 reel/frame not recorded | Midcap Financial Trust, As Agent | Intarcia Therapeutics, Inc. | Release of Security Interest |
| Apr 17, 2020 reel/frame not recorded | Midcap Financial Trust, As Agent | Intarcia Ireland Limited | Release of Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
A terminal disclaimer is on file (approved) and its reference document is not resolved. A disclaimer would cap the term earlier than Feb 10, 2029. We will not guess the cap.